GlassScriptPhysician profile
Barbara B Yosaitis
NPI 1679617997
$7,170.18
in general payments reported to CMS, 2019-2025
36 companies · $1,118 in 2025
The $1,118 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,035 · 2020: $758 · 2021: $1,176 · 2022: $989 · 2023: $1,023 · 2024: $1,071 · 2025: $1,118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,197 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,197.43 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,286.80 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,079.98 | 2019-2025 | Synthroid, Ubrelvy, Qulipta |
| Pfizer INC. | $949.74 | 2019-2025 | |
| Amgen INC. | $590.99 | 2019-2025 | Otezla, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $483.95 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $328.73 | 2019-2024 | Airsupra, Farxiga, Breztri |
| Sanofi-Aventis U.S. LLC | $280.68 | 2019-2022 | |
| Lilly USA, LLC | $253.99 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Janssen Pharmaceuticals, INC | $197.64 | 2019-2024 | Xarelto |
| Abbott Laboratories | $158.97 | 2019-2024 | Freestyle Libre 3, Proclaim |
| Bausch Health US, LLC | $147.65 | 2021-2025 | Aplenzin |
| Esperion Therapeutics, INC. | $125.37 | 2021-2022 | |
| Allergan, INC. | $114.64 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $112.34 | 2019-2024 | Xifaxan |
| Merck Sharp & Dohme LLC | $104.78 | 2019-2025 | Capvaxive |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $87.65 | 2019-2025 | Vpriv |
| Novartis Pharmaceuticals Corporation | $85.03 | 2021-2025 | |
| Horizon Therapeutics Plc | $77.59 | 2023 | Krystexxa |
| Biohaven Pharmaceuticals, INC. | $77.22 | 2021 | |
| Astellas Pharma US INC | $71.66 | 2023-2025 | Veozah |
| Exact Sciences Corporation | $69.79 | 2024-2025 | Cologuard Collection Kit |
| Vanda Pharmaceuticals INC. | $67.94 | 2019-2022 | |
| Amarin Pharma, INC. | $66.16 | 2020-2021 | |
| Myriad Women'S Health, INC. | $54.58 | 2023 | Myrisk |
| Biohaven Pharmaceutical Holding Company LTD. | $48.08 | 2022 | |
| Genzyme Corporation | $36.33 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $30.78 | 2022 | |
| Mylan Specialty L.P. | $25.66 | 2023 | Yupelri |
| Daiichi Sankyo INC. | $23.91 | 2021 | |
| Glaxosmithkline, LLC. | $23.03 | 2023 | Arexvy, Shingrix |
| E.R. Squibb & Sons, L.L.C. | $22.07 | 2022 | |
| Ibsa Pharma INC. | $20.90 | 2022 | |
| Inspire Medical Systems, INC. | $20.82 | 2025 | Inspire |
| Antares Pharma, INC. | $19.09 | 2021 | |
| Idorsia Pharmaceuticals US INC | $12.90 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Yosaitis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.